An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
About the study
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Diagnosis of JIA (any subtype)
- Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
- Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial
- Parent or legally acceptable representative willing to participate in the study and sign the informed consent
EXCLUSION CRITERIA
Exclusion Criteria:
- Pregnant or nursing female at the time of enrollment
- Prior malignancies if the patient has not been malignancy free for at least 5 years.
- Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study
- Known poor compliance with clinic visits (based on physician judgment)
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Juvenile Idiopathic Arthritis
Age
< 17
Participants Needed
800
Est. Completion Date
Jan 2, 2029
Treatment Type
OBSERVATIONAL
Sponsor
Bristol-Myers Squibb
ClinicalTrials.gov NCT Identifier
NCT01357668
Study Number
IM101-240
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?